Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and efficacy of intravenous
(IV) infusion of ulinastatin compared to placebo with respect to time to recovery, disease
severity, need for ventilator support, and mortality in patients with COVID 19.